



Charleston Laboratories, Inc. Appoints Ray Takigiku Ph.D. Chief Operating Officer

Versatile, Experienced and Proven Executive

Charleston, South Carolina – April 28th 2008 – Charleston Laboratories, Inc, an emerging specialty pharmaceutical company dedicated to reducing opioid induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced today the appointment of Ray Takigiku Ph.D. as Chief Operating Officer. Dr. Takigiku is the CEO of Bexion Pharmaceuticals, a pharmaceutical company focusing on the development and commercialization of innovative anti-cancer therapies. He also serves as a board member for other industry organizations in the US and China.

“I could not be more pleased and excited to have Ray as Charleston’s Chief Operating Officer” said Paul Bosse, Chief Executive Officer of Charleston. “He is a versatile, experienced, and proven executive with over 20 years of drug discovery and development experience. Ray is a natural fit with Charleston’s long term growth strategy and brings tremendous exposure to biotech communities all over the world. Ray’s unique understanding of Charleston’s core technology and its application to other cutting edge technologies will prove invaluable to the continued growth of the company. I look forward to working with Ray day in and day out”

Mr. Takigiku was previously the Director of Discovery Core Technologies, Analytical and Bioanalytical for Procter & Gamble Pharmaceuticals, and also Interim co-Director of the Genome Research Institute of the College of Medicine University of Cincinnati. At P&G, he led development and implementation of new technologies to discover and develop novel drugs, and he was part of the leadership team behind Actonel, the blockbuster osteoporosis drug. He has more than 18 years industry experience in drug discovery and development within a large pharmaceutical company setting. Dr. Takigiku participated in the filing of several INDs and multiple NDAs, ANDAs, and sNDAs. Dr. Takigiku received his BA from University of Colorado and Ph.D. from Indiana University.

"I am very excited to be a part of the Charleston Labs team. Their core technology is innovative and will meet patient needs for pain relief with minimal or no opioid-induced nausea and vomiting (OINV) side effects. I believe my professional experience in drug development, commercialization, and in forming industry relationships is a good fit with the rest of the Charleston Labs team and will help us to expedite development of these greatly needed therapeutics."



About Charleston Laboratories, Inc.

Charleston Laboratories Inc, headquartered in Charleston, SC, is a privately funded specialty pharmaceutical company developing and commercializing opioid drugs with minimal or no opioid-induced nausea and vomiting (OINV). Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.

www.charlestonlabs.com.

###